PD61-07 GLOBAL GREENLIGHT GROUP: LARGEST INTERNATIONAL GREENLIGHT EXPERIENCE FOR BENIGN PROSTATIC HYPERPLASIA

Abstract

INTRODUCTION AND OBJECTIVE: Amongst the surgical treatment modalities available, Greenlight photo-selective vaporization of the prostate (GL-PVP) has gained international acceptance as a safe and effective alternative procedure for the treatment of BPH, with hemostatic benefits particularly in anticoagulated men. This descriptive analysis aims to characterize the current state of GL-PVP, pooling intra- and postoperative outcomes from multiple academic centres globally. METHODS: Data from 2143 patients who underwent Greenlight 180W-XPS PVP in 5 international centres by 6 expert surgeons between 2010 and 2019, was retrospectively analyzed. Demographic, peri- and postoperative data was collected, including IPSS, QOL, Qmax, PVR, and PSA. Clavien-Dindo postoperative adverse events were also assessed. RESULTS: Median age, prostate volume, PSA and IPSS was 68 years (IQR 63-75), 64cc (49-88), 3.1 ng/mL (1.7-5.0) and 23 (20-28), respectively. Median lasing time was 30 min (21-41) during a median 60 min (45-80) procedure. Median energy use was 244 kJ (166-355), with 92.5% of procedures being completed with 1 laser fiber. In 63% of cases, Foley catheter was removed on postoperative day 1 with 84.8% of men being discharged within 2 days of admission. The 30-day postoperative readmission rate was 3.9%, while major cardiac events and death occurred in 0.8% and 0.3% of cases respectively. Prostatic adenocarcinoma was found on tissue pathology in 2.3% of cases. Median PSA reduction at 12 months, 24 months and 60 months was 46.3%, 59.7% and 51.4% respectively. CONCLUSIONS: To the best of our knowledge, from the largest multi-user, international experience, GreenLight PVP of the prostate is a safe, effective and durable BPH procedure. (Table Presented).